WaveMan
WaveMan · Company
PBLS · Parabilis Medicines, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PBLS Parabilis Medicines (PBLS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001657677
Quote by TradingView
Cluster · 4 insidersActivist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
80
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $5.0M priced

What the filings say about PBLS

Insiders, 180 days
+$441.4M net bought
4 buyers
Activist stakes (13D), 180 days
1 filing
Largest: 23.8% of the class

Parabilis Medicines insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Parabilis Medicines, Inc. insiders bought a net $441.4M of stock across 14 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-22 SEC
47,250
$1.4M
-25.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Jul 21, 2026.
  • -11.4% median (-11.4% mean) 90-day return after 2 previous buys.
  • The trade is 0.2% of the 26,529,686 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. bought about $1.4M of PBLS on Jul 22, 2026; 80 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-22 SECtraded 2026-07-21
21,696
$606.6K
-25.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 20, 2026.
  • The trade is 0.1% of the 26,438,209 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. bought about $606.6K of PBLS on Jul 21, 2026; 80 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-22 SECtraded 2026-07-21
6,504
$189.7K
-25.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 20, 2026.
  • The trade is 0.0% of the 26,444,713 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. bought about $189.7K of PBLS on Jul 21, 2026; 80 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-22 SECtraded 2026-07-21
37,723
$1.1M
-25.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 20, 2026.
  • The trade is 0.1% of the 26,482,436 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. bought about $1.1M of PBLS on Jul 21, 2026; 80 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-07-22 SECtraded 2026-07-20
98,433
$2.7M
-25.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.4% of the 26,383,526 shares held after it.
  • No other insider bought within 30 days.
  • 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. bought about $2.7M of PBLS on Jul 20, 2026; 80 funds added in the latest 13F quarter.
14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 9 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$441.4M over 180 days
+$440.7M of it by a 10%+ holder
the highest in Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
80 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
10.1% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
The situation: each line is one rule over one dataset
RA Capital Management, L.P. disclosed a 5%+ stake (23.8%) in the last six months.
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 14 in the prior 90
Why it matters
The absence is the signal: 14 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch PBLS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-22.7%12M
-28%-8%+12%+32%2026-062026-072026-072026-082026-092026-092026-10 2026-06-11 · RA Capital Nexus Fund III, L.P. bought $394.6M2026-06-11 · RA Capital Nexus Fund III, L.P. bought $29.2M2026-06-11 · Soleus Capital Group, LLC bought $7.5M2026-07-20 · RA CAPITAL MANAGEMENT, L.P. bought $2.7M2026-06-11 · Soleus Capital Group, LLC bought $2.5M2026-07-22 · RA CAPITAL MANAGEMENT, L.P. bought $1.4M2026-07-21 · RA CAPITAL MANAGEMENT, L.P. bought $1.1M2026-07-20 · RA CAPITAL MANAGEMENT, L.P. bought $914.4K2026-07-21 · RA CAPITAL MANAGEMENT, L.P. bought $606.6K2026-06-11 · SEBULSKY ALAN bought $250.0K2026-06-12 · SEBULSKY ALAN bought $233.4K2026-07-21 · RA CAPITAL MANAGEMENT, L.P. bought $189.7K2026-06-15 · SEBULSKY ALAN bought $130.0K2026-06-15 · SEBULSKY ALAN bought $110.2K2026-06-18 · RA Capital Management, L.P. filed a 5%+ stake (23.8%)2026-06-18 · Peter Kolchinsky filed a 5%+ stake (23.8%)2026-06-18 · Rajeev Shah filed a 5%+ stake (23.8%)2026-06-18 · RA Capital Healthcare Fund, L.P. filed a 5%+ stake (21.6%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PBLS: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
28,933,371 sh
$791.9M
FMR LLC
10,292,735 sh
$281.7M
ARCH Venture Management, LLC
6,412,780 sh
$175.5M
venBio Partners LLC
5,266,697 sh
$144.1M
Alphabet Inc.
4,919,498 sh
$134.6M

Congress trades in PBLS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
RA Capital Management, L.P.
Activist 13D · 2026-06-18
23.8%
Peter Kolchinsky
Activist 13D · 2026-06-18
23.8%
Rajeev Shah
Activist 13D · 2026-06-18
23.8%
RA Capital Healthcare Fund, L.P.
Activist 13D · 2026-06-18
21.6%

PBLS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PBLS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
JPMorgan Small Cap Growth Fund
$13.1M position · as of 2026-06-30
0.5%
Small Cap Core Portfolio
$3.5M position · as of 2026-06-30
0.4%
AB Small Cap Growth Portfolio
$172.3K position · as of 2026-06-30
0.3%
AB Small Cap Growth Portfolio
$9.0M position · as of 2026-06-30
0.3%
Franklin Biotechnology Discovery Fund
$3.2M position · as of 2026-07-31
0.3%
MFS New Discovery Series
$2.2M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $441.4M bought by insiders over 180 days, 80 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PBLS financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
0.01x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

PBLS Stock Sonar score 4/7 axes

Find similar shapesCompare

PBLS ranks highest on insider conviction (97th percentile) and financial health (78th), and lowest on risk and compliance (39th), among Pharma & Biotech peers.

Financial health
78
Inputs
  • Debt to equity0.01x · 78 pct, sector of 352
  • Cash flow to debtneeds four quarters of operating cash flow
Insider conviction
97
Inputs
  • Net Form 4 buying (codes P and S), 180d$441.4M · 100 pct, sector of 428
  • Insider buyers, 180d4 · 94 pct, sector of 437
Institutional and government
60
Inputs
  • Funds adding, latest quarter80 · 60 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+10.1% · 39 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Growth, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PBLS filings, in plain words

Are Parabilis Medicines insiders buying or selling PBLS?

In the 180 days to 2026-10-27, Parabilis Medicines insiders were net buyers, a net $441.4M across purchases and sales reported on Form 4, by 4 buyers.

Read the full summary

In the 180 days to 2026-10-27, Parabilis Medicines insiders were net buyers of PBLS, a net $441.4M across purchases and sales reported on Form 4 by 4 buyers. Most of that figure, $440.7M, came from a holder of 10% or more rather than an officer or director. 4 insiders reported purchases in that window. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 23.8% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies